Maira M - Search Results

1

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK. Engelman JA, et al. Among authors: maira m. Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30. Nat Med. 2008. PMID: 19029981 Free PMC article.

2

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J. Serra V, et al. Among authors: maira m. Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385. Cancer Res. 2008. PMID: 18829560

3

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.

Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, Robert CL, Kluger HM. Elfiky AA, et al. Among authors: maira m. J Transl Med. 2011 Aug 11;9:133. doi: 10.1186/1479-5876-9-133. J Transl Med. 2011. PMID: 21834980 Free PMC article.

4

Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.

O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM. O'Reilly T, et al. Among authors: maira m. Cancer Chemother Pharmacol. 2008 Nov;62(6):1045-54. doi: 10.1007/s00280-008-0695-9. Epub 2008 Feb 27. Cancer Chemother Pharmacol. 2008. PMID: 18301895

5

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.

Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, Jamin Y, Robinson SP, Pearson A, Maira M, Weiss WA, Workman P, Chesler L. Vaughan L, et al. Among authors: maira m. Oncotarget. 2016 Sep 6;7(36):57525-57544. doi: 10.18632/oncotarget.10544. Oncotarget. 2016. PMID: 27438153 Free PMC article.

6

Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

Fairhurst RA, Furet P, Imbach-Weese P, Stauffer F, Rueeger H, McCarthy C, Ripoche S, Oswald S, Arnaud B, Jary A, Maira M, Schnell C, Guthy DA, Wartmann M, Kiffe M, Desrayaud S, Blasco F, Widmer T, Seiler F, Gutmann S, Knapp M, Caravatti G. Fairhurst RA, et al. Among authors: maira m. J Med Chem. 2022 Jun 23;65(12):8345-8379. doi: 10.1021/acs.jmedchem.2c00267. Epub 2022 May 2. J Med Chem. 2022. PMID: 35500094

7

Dynamic conformational equilibria in the active states of KRAS and NRAS.

Rennella E, Henry C, Dickson CJ, Georgescauld F, Wales TE, Erdmann D, Cotesta S, Maira M, Sedrani R, Brachmann SM, Ostermann N, Engen JR, Kay LE, Beyer KS, Wilcken R, Jahnke W. Rennella E, et al. Among authors: maira m. RSC Chem Biol. 2024 Nov 25. doi: 10.1039/d4cb00233d. Online ahead of print. RSC Chem Biol. 2024. PMID: 39664928 Free PMC article.

8

Pharmacological interrogation of TrkA-mediated mechanisms in hippocampal-dependent memory consolidation.

Josephy-Hernandez S, Pirvulescu I, Maira M, Aboulkassim T, Wong TP, McKinney RA, Saragovi HU. Josephy-Hernandez S, et al. Among authors: maira m. PLoS One. 2019 Jun 24;14(6):e0218036. doi: 10.1371/journal.pone.0218036. eCollection 2019. PLoS One. 2019. PMID: 31233568 Free PMC article.

9

Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy.

Tong W, Maira M, Roychoudhury R, Galan A, Brahimi F, Gilbert M, Cunningham AM, Josephy S, Pirvulescu I, Moffett S, Saragovi HU. Tong W, et al. Among authors: maira m. Cell Chem Biol. 2019 Jul 18;26(7):1013-1026.e4. doi: 10.1016/j.chembiol.2019.03.018. Epub 2019 May 16. Cell Chem Biol. 2019. PMID: 31105061 Free article.

10

The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS.

Brahimi F, Maira M, Barcelona PF, Galan A, Aboulkassim T, Teske K, Rogers ML, Bertram L, Wang J, Yousefi M, Rush R, Fabian M, Cashman N, Saragovi HU. Brahimi F, et al. Among authors: maira m. PLoS One. 2016 Oct 3;11(10):e0162307. doi: 10.1371/journal.pone.0162307. eCollection 2016. PLoS One. 2016. PMID: 27695040 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters